Glucose Control Indicators for Infant Neurodevelopmental Risk

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods fail to accurately assess chronic glucose regulation in infants, particularly in premature infants, which is crucial for identifying the risk of neurodevelopmental disorders such as retinopathy of prematurity and cerebral palsy, as existing glucose control indicators like Hemoglobin A1c are not validated for use in infants or pregnant women.

Innovation Solution

The use of glucose control indicators like glycated hemoglobin and glycated albumin fractions, calculated relative to total whole blood protein, to assess chronic glucose status over extended periods, providing a comprehensive glucose control indicator that is applicable during infancy and pregnancy, allowing for early detection and treatment of developmental diabetes and associated neurodevelopmental disorders.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If Hemoglobin A1c is used as a glucose control indicator, then glucose control can be assessed, but it cannot be validated for use in infants or pregnant women

Engineering Contradiction:

Improveglucose control assessment accuracyVSAvoidapplicability to infants and pregnant women

Core Design Contradiction:

Measurement precisionVSAdaptability or versatility

Solution Approach 1:

The patent changes the parameter basis for glucose control assessment from Hemoglobin A1c to glucose control indicators calculated relative to total whole blood protein. This parameter change enables valid assessment in infants and pregnant women whose hemoglobin levels and composition differ from adults, thus resolving the limitation of A1c validation while maintaining measurement precision

Inventive Principle:

Principle #35Parameter changes

2Loss of information

If chronic glucose regulation is assessed using existing methods, then some glucose status information can be obtained, but accurate risk assessment for neurodevelopmental disorders cannot be achieved

Engineering Contradiction:

Improveglucose status information completenessVSAvoidneurodevelopmental disorder risk assessment reliability

Core Design Contradiction:

Loss of informationVSReliability

Solution Approach 1:

The patent replaces the conventional Hemoglobin A1c measurement system with a new calculation system based on glucose control indicators relative to total whole blood protein. This substitution provides more complete glucose status information and enables reliable neurodevelopmental disorder risk assessment in infant populations where A1c fails

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

3Reliability

If glucose control indicators are not used in infancy and pregnancy, then existing validated methods can be applied, but early detection and treatment of developmental diabetes cannot occur

Engineering Contradiction:

Improvemethod validation reliabilityVSAvoidearly detection timing

Core Design Contradiction:

ReliabilityVSLoss of time

Solution Approach 1:

The patent enables preliminary glucose control assessment during critical periods of infancy and pregnancy by introducing validated glucose control indicators calculated relative to total whole blood protein. This preliminary action allows early detection and treatment of developmental diabetes before neurodevelopmental disorders manifest, overcoming the timing limitation of existing methods

Inventive Principle:

Principle #10Preliminary action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach enables accurate monitoring of chronic dysglycemia, allowing for timely intervention and reducing the risk of neurodevelopmental disorders by providing a reliable method for assessing glucose control in infants and pregnant women, overcoming the limitations of existing methods.

Implementation Method 1

The use of glucose control indicators like glycated hemoglobin and glycated albumin fractions, calculated relative to total whole blood protein, to assess chronic glucose status over extended periods

Methodology Applied

Scientific EffectGlycation: Chemical Bonding

Data Source

PatentUS20230022094A1Use of Glucose Control Indicators for Risk Assessment and Treatment of Neurodevelopmental Disorders and Techniques for Establishing the Status of Chronic Glucose Control

Publication Date: 2023.01.26 MOVSAS TAMMY

AI summary

Dysglycemia as a risk factor for neurodevelopmental disorder or developmental diabetes. The risk is assessed based on measurement of a glucose control indicator in a blood sample. One particular example of a neurodevelopmental disorder is retinopathy of prematurity in an infant. One particular example of a glucose control indicator is ‘comprehensive glycated hemoglobin fraction’ or ‘comprehensive glycated albumin fraction.’ This is calculated using ‘total whole blood protein’ in the denominator. In the case of chronic hyperglycemia, there is an increased risk of proliferative retinopathy of prematurity. In the case of chronic hypoglycemia, there is an increased risk of non-proliferative retinopathy of prematurity. This ‘total whole blood protein’ technique could also be used to determine the glucose control status in other types of patients.